Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
FYI: (The Linkster owns two of the funds mentioned, PRHSX & FBTCX, in the article) (Note for high risk-tolerent investors) Highly risk-tolerant investors who believe biotechnology will grow in 2016 should consider mutual funds that have a high portfolio allocation to the biotech sector. These mutual funds provide professionally managed exposure to the sector and helps to minimize costs while investing in many stocks related to biotech, pharmaceuticals and health care.
